Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®

RegulatoryapprovedLeqembiPositive

AI Analysis

Summary

Canada's Drug Agency issued a final positive recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible patients with mild cognitive impairment. The recommendation was announced by Eisai, partner to BioArctic AB.

Outcome Details

Final positive recommendation supporting public reimbursement in Canada

Importance:7/10

Sentiment:

0.85

regulatory approvalreimbursementCanadaLeqembilecanemabBioArcticEisai

Related Companies

$BIOA-B.ST $ESALY

Read the original article

Published by PR Newswire Biotech on September 1, 2026 5:25 AM

Read Original